This is what analysts have to say about T2 Biosystems, Inc. (NASDAQ:TTOO) after last week.

T2 Biosystems, Inc. (NASDAQ:TTOO) Logo

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Coverage

Among 2 analysts covering T2 Biosystems (NASDAQ:TTOO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. T2 Biosystems has $500 highest and $0.4000 lowest target. $2.70’s average target is -6.25% below currents $2.88 stock price. T2 Biosystems had 8 analyst reports since May 13, 2019 according to SRatingsIntel. Leerink Swann maintained T2 Biosystems, Inc. (NASDAQ:TTOO) on Thursday, September 12 with “Outperform” rating. The stock has “Neutral” rating by Alliance Global Partners on Thursday, August 1. Below is a list of T2 Biosystems, Inc. (NASDAQ:TTOO) latest ratings and price target changes.

12/09/2019 Broker: Leerink Swann Rating: Outperform Old Target: $3.0000 New Target: $5.0000 Maintain
12/09/2019 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Upgrade
01/08/2019 Broker: Alliance Global Partners Old Rating: Buy New Rating: Neutral Old Target: $5.0000 New Target: $0.4000 Downgrade
31/07/2019 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Downgrade
31/07/2019 Broker: Janney Capital Old Rating: Buy New Rating: Neutral Downgrade
19/05/2019 Broker: BidaskScore Rating: Hold Upgrade
16/05/2019 Broker: Inc. – Common Stock Rating: Alliance Global Partners 5.0000
13/05/2019 Broker: BidaskScore Rating: Sell Upgrade

The stock decreased 4.32% or $0.13 during the last trading session, reaching $2.88. About 4.48 million shares traded or 134.39% up from the average. T2 Biosystems, Inc. (NASDAQ:TTOO) has declined 89.90% since September 13, 2018 and is downtrending. It has underperformed by 89.90% the S&P500.

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The company has market cap of $147.92 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. It currently has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

More notable recent T2 Biosystems, Inc. (NASDAQ:TTOO) news were published by: Globenewswire.com which released: “T2 Biosystems to Present at the Janney Healthcare Conference 2019 – GlobeNewswire” on August 29, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 08/16/2019: TDOC,TTOO,ARAY – Nasdaq” published on August 16, 2019, Nasdaq.com published: “Health Care Sector Update for 09/11/2019: ABIO,TTOO,LXRX,TLRY – Nasdaq” on September 11, 2019. More interesting news about T2 Biosystems, Inc. (NASDAQ:TTOO) were released by: Benzinga.com and their article: “12 Healthcare Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” published on August 27, 2019 as well as Benzinga.com‘s news article titled: “23 Healthcare Stocks Moving In Thursday’s Pre-Market Session – Benzinga” with publication date: August 29, 2019.

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.